Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
FDA Approves New Treatment Option for Sleep Apnea
FDA news release; 2017 Oct 6
The US Food and Drug Administration (FDA) has approved a new treatment option for patients who have been diagnosed with moderate-to-severe central sleep apnea. The Remedē System, manufactured by Respicardia, Inc., is an implantable device that stimulates a nerve located in the chest that is responsible for sending signals to the diaphragm to stimulate breathing. Respicardia, Inc. is headquartered in Minnetonka, MN.
Indications: The Remedē System is comprised of a battery pack surgically placed under the skin in the upper chest area and small, thin wires that are inserted into the blood vessels in the chest near the nerve (phrenic) that stimulates breathing. The system monitors the patient’s respiratory signals during sleep and stimulates the nerve to move the diaphragm and restore normal breathing.
Adverse effects: The most common adverse events reported included concomitant device interaction, implant site infection, and swelling and local tissue damage or pocket erosion. The Remedē System should not be used by patients with an active infection or by patients who are known to require magnetic resonance imaging.
FDA approves implantable device to treat moderate to severe central sleep apnea. [news release]. Minnetonka, MN: Respicardia, Inc. October 6, 2017. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm579506.htm. Accessed October 9, 2017.
This Week's Must Reads
Must Reads in FDA Actions
FDA Approves Inbrija for PD OFF Episodes, Acorda Therapeutics news release; 2018 Dec 21
FDA Approves Firdapse for Rare Autoimmune Disorder, FDA news release; 2018 Nov 28
FDA Approves Ajovy for Migraine in Adults, Teva Pharmaceutical news release; 2018 Sep 14
FDA Approves Tiglutik for Treatment of ALS, ITF Pharma news release; 2018 Sep 6
FDA Approves Diacomit for Treatment of Seizures, Biocodex news release; 2018 Aug 23